Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement

Simply Wall St.01-25 14:32

AdvertisementWhat the Eisai partnership means for Nuvation Bio Nuvation Bio (NUVB) has drawn fresh attention after signing an exclusive license and collaboration agreement with Eisai covering ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606125901?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-01-25 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606125901","market":"sg","top_or_hot":-1,"title":"Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat the Eisai partnership means for Nuvation Bio Nuvation Bio (NUVB) has drawn fresh attention after signing an exclusive license and collaboration agreement with Eisai covering ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-after-the-eisai-taletr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-25 14:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-after-the-eisai-taletr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat the Eisai partnership means for Nuvation Bio Nuvation Bio (NUVB) has drawn fresh attention after signing an exclusive license and collaboration agreement with Eisai covering ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-after-the-eisai-taletr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-after-the-eisai-taletr","article_id":"2606125901","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-after-the-eisai-taletr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606125901","pubTimestamp":1769322762,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What the Eisai partnership means for Nuvation Bio\nNuvation Bio (NUVB) has drawn fresh attention after signing an exclusive license and collaboration agreement with Eisai covering taletrectinib for ROS1-positive non small cell lung cancer across multiple international markets.\nUnder the deal, Nuvation Bio is set to receive an upfront payment of €50 million, potential regulatory and commercial milestones of up to €145 million, and double digit tiered royalties on future net sales in Eisai’s...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NUVB":"Nuvation Bio, Inc."},"translate_title":"卫材宣布Taletrectinib合作伙伴关系后评估Nuvation Bio(NUVB)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":1.5},"content_text":"AdvertisementWhat the Eisai partnership means for Nuvation Bio Nuvation Bio (NUVB) has drawn fresh attention after signing an exclusive license and collaboration agreement with Eisai covering taletrectinib for ROS1-positive non small cell lung cancer across multiple international markets. Under the deal, Nuvation Bio is set to receive an upfront payment of €50 million, potential regulatory and commercial milestones of up to €145 million, and double digit tiered royalties on future net sales in Eisai’s licensed territories. See our latest analysis for Nuvation Bio. The Eisai agreement lands after a sharp 40.53% 1 month share price decline and a 5.41% 1 day drop to US$5.59. However, the 1 year total shareholder return of 121.83% and 3 year total shareholder return of roughly 2.3x suggest longer term momentum has previously been strong, even as recent share price performance has cooled. If this deal has you looking across oncology and drug development, it could be a useful moment to scan other healthcare stocks that might fit your watchlist next. With the Eisai deal in place, a 1 year total return above 120% and a recent 1 month slide of more than 40%, you have to ask yourself: is Nuvation Bio mispriced today, or is the market already assuming future growth? Most Popular Narrative: 45.5% Undervalued The most followed narrative puts Nuvation Bio's fair value at $10.25 compared with the last close of $5.59, indicating a wide valuation gap to consider.  Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI.  Read the complete narrative. Want to see what is driving that kind of upside gap? The narrative emphasizes sharp revenue growth, a shift toward profitability and a future earnings multiple that is anything but ordinary. Result: Fair Value of $10.25 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upside story can unravel if IBTROZI faces tougher competition than expected or if safusidenib timelines slip, which would keep Nuvation Bio reliant on a single key asset. Find out about the key risks to this Nuvation Bio narrative. Another way to look at Nuvation Bio’s value The first narrative leans heavily on future earnings to call Nuvation Bio undervalued at $10.25 per share. Our DCF model presents an even more aggressive picture, with a future cash flow value of $42.41, which is very far above the current $5.59 share price. The gap between those two fair values suggests that small changes in assumptions about revenue growth, profitability or timing can significantly affect the outcome. That kind of spread can look appealing, but it also raises a simple question for you: which set of assumptions do you trust more? Look into how the SWS DCF model arrives at its fair value. NUVB Discounted Cash Flow as at Jan 2026 Build Your Own Nuvation Bio Narrative If you see the story differently, or simply prefer to weigh the numbers yourself, you can shape a custom view in just a few minutes with Do it your way. A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you only focus on one company, you could miss other opportunities waiting in plain sight, so take a few minutes to scan fresh ideas before markets move.  Spot potential bargains by checking out these 872 undervalued stocks based on cash flows that the market may be pricing conservatively based on their cash flows. Explore companies involved in artificial intelligence by reviewing these 24 AI penny stocks that are building products and services around AI. Target income-focused opportunities by scanning these 13 dividend stocks with yields > 3% that currently offer yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nuvation Bio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606125901","isCrawlerRequest":true}